ABSTRACT
In 1983, Coates et al. published a patient survey showing that vomiting and nausea were respectively the first and second most distressing side effects of cancer chemotherapy (1).
In the following years, a better understanding of the pathophysiology of chemotherapy-induced emesis and the introduction of the 5-HT3 antagonists in clinical practice determined a significant increase in complete protection from nausea and vomiting. In this review, progress is reported and practical guidelines for the prevention of chemotherapy-induced emesis are suggested.
